seems that the post was made more recently so enabled it to be picked up before manufacture was finalised.
So potentially it relates to the formulation, creating a new drug perhaps allowing it to obtain orphan drug designation and extending protection. Know there are conditions around this so may be wrong.
Biotargo had some great ideas about the clinical trials but nothing about formulation stands out.
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-231
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
-0.040(2.23%) |
Mkt cap ! $297.9M | |||
| Open | High | Low | Value | Volume |
| $1.79 | $1.79 | $1.72 | $146.2K | 83.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2901 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 994 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.74 |
Change
-0.040 ( 1.51 %) |
||||
| Open | High | Low | Volume | ||
| $1.76 | $1.77 | $1.72 | 23546 | ||
| Last updated 15.56pm 17/06/2024 ? | |||||
| RAC (ASX) Chart |
